Panic disorder and migraine: Comorbidity, mechanisms, and clinical implications

Headache

Volumn 53, Issue 1, 2013, Pages 23-45

  Smitherman, Todd A ^a   Kolivas, Elizabeth D ^a   Bailey, Jennifer R ^a  

^a UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

anxiety; comorbidity; headache; migraine; panic disorder

Indexed keywords

AMITRIPTYLINE; ATENOLOL; CAFFEINE; CITALOPRAM; ESCITALOPRAM; FLUVOXAMINE; METOPROLOL; NADOLOL; PAROXETINE; PROPRANOLOL; SERTRALINE; TIMOLOL; TOPIRAMATE; VALPROATE SEMISODIUM; VENLAFAXINE;

ADRENERGIC SYSTEM; AGORAPHOBIA; ALCOHOL CONSUMPTION; ANTICIPATORY ANXIETY; ANXIETY DISORDER; ANXIETY SENSITIVITY INDEX; AVOIDANCE BEHAVIOR; BECK ANXIETY INVENTORY; BEHAVIOR THERAPY; CHRONIC DISEASE; CHRONIC PAIN; COGNITION; COGNITIVE THERAPY; COMORBIDITY; DEPRESSION; DIZZINESS; DRUG INDUCED HEADACHE; EMOTIONAL DISORDER; EPISODIC MIGRAINE; EVIDENCE BASED PRACTICE; FUNCTIONAL DISEASE; GENERALIZED ANXIETY DISORDER; HEADACHE; HELP SEEKING BEHAVIOR; HUMAN; MAJOR DEPRESSION; MIGRAINE; MIGRAINE WITH AURA; MIGRAINE WITHOUT AURA; NAUSEA; ONSET AGE; PAIN; PANIC; PHYSICAL ACTIVITY; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSITIZATION; SEROTONINERGIC SYSTEM; SOCIAL PHOBIA; SPREADING CORTICAL DEPRESSION; STATE TRAIT ANXIETY INVENTORY; SUBSTANCE ABUSE; SUICIDAL IDEATION; SUICIDE; TRANSFORMED MIGRAINE;

COMORBIDITY; HUMANS; MIGRAINE DISORDERS; PANIC DISORDER;

EID: 84872108652     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/head.12004     Document Type: Review

References (170)

1. Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF,. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007; 68: 343-349.
2. Edmeads J, Mackell JA,. The economic impact of migraine: An analysis of direct and indirect costs. Headache. 2002; 42: 501-509.
3. Terwindt GM, Ferrari MD, Tijhuis M, Groenen SMA, Picavet HSJ, Launer LJ,. The impact of migraine on quality of life in the general population: The GEM study. Neurology. 2000; 55: 624-629.
4. Stovner LJ, Hagen K, Jensen R, et al. The global burden of headache: A documentation of headache prevalence and disability worldwide. Cephalalgia. 2007; 27: 193-210.
5. Leonardi M, Steiner TJ, Scher AT, Lipton RB,. The global burden of migraine: Measuring disability in headache disorders with WHO's Classification of Functioning, Disability, and Health (ICF). J Headache Pain. 2005; 6: 429-440.
6. Breslau N, Rasmussen BK,. The impact of migraine: Epidemiology, risk factors, and co-morbidities. Neurology. 2001; 56 (Suppl. 1): 4-12.
7. Schoenen J, Dodick DW, Sándor P, eds. Comorbidity in Migraine. Hoboken, NJ: Wiley-Blackwell; 2011.
8. Wang SJ, Chen PK, Fuh JL,. Comorbidities of migraine. Front Neurol. 2010; 1: 16.
9. Bigal ME, Lipton RB,. Modifiable risk factors for migraine progression. Headache. 2006; 46: 1334-1343.
10. Dodick DW,. Review of comorbidities and risk factors for the development of migraine complications (infarct and chronic migraine). Cephalalgia. 2009; 29 (Suppl. 3): 7-14.
11. Breslau N,. Psychiatric comorbidity in migraine. Cephalalgia. 1998; 18 (Suppl. 22): S56-S61.
12. Hamelsky SW, Lipton RB,. Psychiatric comorbidity of migraine. Headache. 2006; 46: 1327-1333.
13. Radat F, Swendsen J,. Psychiatric comorbidity in migraine: A review. Cephalalgia. 2005; 25: 165-178.
14. Breslau N, Merikangas K, Bowden CL,. Comorbidity of migraine and major affective disorders. Neurology. 1994; 44 (Suppl. 7): S17-S22.
15. Breslau N, Schultz LR, Stewart WF, Lipton RB, Lucia VC, Welch KMA,. Headache and major depression: Is the association specific to migraine. Neurology. 2000; 54: 308-313.
16. Breslau N, Lipton RB, Stewart WF, Schultz LR, Welch KM,. Comorbidity of migraine and depression: Investigating potential etiology and prognosis. Neurology. 2003; 60: 1308-1312.
17. Lipton RB, Hamelsky SW, Kolodner KB, Steiner TJ, Stewart WF,. Migraine, quality of life, and depression: A population-based case control study. Neurology. 2000; 55: 629-635.
18. Maizels M, Smitherman TA, Penzien DB,. A review of screening tools for psychiatric comorbidity in headache patients. Headache. 2006; 46 (Suppl. 3): S98-S109.
19. Smitherman TA, Penzien DB, Maizels M,. Anxiety disorders and migraine intractability and progression. Curr Pain Headache Rep. 2008; 12: 224-229.
20. Kessler RC, Berglund P, Demler O, Jin R, Walters EE,. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005; 62: 593-602.
21. Saunders K, Merikangas K, Low NCP, Von Korff M, Kessler RC,. Impact of comorbidity on headache-related disability. Neurology. 2008; 70: 538-547.
22. Zwart JA, Dyb G, Hagen K, et al. Depression and anxiety disorders associated with headache frequency. The Nord-Trøndelag Health Study. Eur J Neurol. 2003; 10: 147-152.
23. Lantéri-Minet M, Radat F, Chautart MH, Lucas C,. Anxiety and depression associated with migraine: Influence on migraine subjects' disability and quality of life, and acute migraine management. Pain. 2005; 118: 319-326.
24. Guidetti V, Galli F, Fabrizi P, et al. Headache and psychiatric comorbidity: Clinical aspects and outcome in an 8-year follow-up study. Cephalalgia. 1998; 18: 455-462.
25. McWilliams LA, Cox BJ, Enns MW,. Mood and anxiety disorders associated with chronic pain: An examination in a nationally representative sample. Pain. 2003; 106: 127-133.
26. McWilliams LA, Goodwin RD, Cox BJ,. Depression and anxiety associated with three pain conditions: Results from a nationally representative sample. Pain. 2004; 111: 77-83.
27. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn, text revision. Washington, DC: American Psychiatric Association; 2000.
28. Kessler RC, Chiu WT, Jin R, Ruscio AM, Shear K, Walters EE,. The epidemiology of panic attacks, panic disorder, and agoraphobia in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2006; 63: 415-424.
29. Kessler RC, Chiu WT, Demler O, Walters EE,. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005; 62: 617-627.
30. Craske MG,. Origins of Phobias and Anxiety Disorders: Why More Women Than Men? Oxford: Elsevier; 2003.
31. Candilis PJ, McLean RY, Otto MW, et al. Quality of life in patients with panic disorder. J Nerv Ment Dis. 1999; 187: 429-434.
32. Lochner C, Mogotsi M, du, Toit PL, Kaminer D, Niehaus DJ, Stein DJ,. Quality of life in anxiety disorders: A comparison of obsessive-compulsive disorder, social anxiety disorder, and panic disorder. Psychopathology. 2003; 36: 255-262.
33. Roy-Byrne PP, Stein MB, Russo J, et al. Panic disorder in the primary care setting: Comorbidity, disability, service utilization, and treatment. J Clin Psychiatry. 1999; 60: 492-499.
34. Markowitz JS, Weissman MM, Oullette R, et al. Quality of life in panic disorder. Arch Gen Psychiatry. 1989; 46: 984-992.
35. Weissman MW, Klerman GL, Markowitz JS, Oullette R,. Suicidal ideation and suicide attempts in panic disorder and panic attacks. N Engl J Med. 1989; 321: 1209-1214.
36. Vickers K, McNally RJ,. Panic disorder and suicide attempt in the National Comorbidity Survey. J Abnorm Psychol. 2004; 113: 582-591.
37. Huffman JC, Pollack MH,. Predicting panic disorder among patients with chest pain: An analysis of the literature. Psychosomatics. 2003; 44: 222-236.
38. Fleet RP, Dupuis G, Marchand A, Burelle D, Arsenault A, Beitman BD,. Panic disorder in emergency department chest pain patients: Prevalence, comorbidity, suicidal ideation, and physician recognition. Am J Med. 1996; 101: 371-380.
39. Haut SR, Bigal ME, Lipton RB,. Chronic disorders with episodic manifestations: Focus on epilepsy and migraine. Lancet Neurol. 2006; 5: 148-157.
40. International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias, and facial pain. Cephalalgia. 1988; 8 (Suppl. 7): S1-S96.
41. International Headache Society. The International Classification of Headache Disorders, 2nd edition. Cephalalgia. 2004; 24 (Suppl. 1): S1-S151.
42. Zigmond AS, Snaith RP,. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand. 1983; 67: 361-370.
43. Brennan C, Worrall-Davies A, McMillan D, Gilbody S, House A,. The Hospital Anxiety and Depression Scale: A diagnostic meta-analysis of case-finding ability. J Psychosom Res. 2010; 69: 371-378.
44. Cosco TD, Doyle F, Ward M, McGee H,. Latent structure of the Hospital Anxiety and Depression Scale: A 10-year systematic review. J Psychosom Res. 2012; 72: 180-184.
45. Coyne JC, van Sonderen E,. No further research needed: Abandoning the Hospital and Anxiety Depression Scale (HADS). J Psychosom Res. 2012; 72: 173-174.
46. Berkson J,. Limitations of the application of the fourfold table analysis to hospital data. Biometrics Bulletin. 1946; 2: 47-53.
47. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 3rd edn, revised. Washington, DC: American Psychiatric Association; 1987.
48. Merikangas KR, Merikangas JR, Angst J,. Headache syndromes and psychiatric disorders: Association and familial transmission. J Psychiatr Res. 1993; 27: 197-210.
49. Wang SJ, Juang KD, Fuh JL, Lu SR,. Psychiatric comorbidity and suicide risk in adolescents with chronic daily headache. Neurology. 2007; 68: 1468-1473.
50. Breslau N, Schultz LR, Stewart WF, Lipton R, Welch KMA,. Headache types and panic disorders: Directionality and specificity. Neurology. 2001; 56: 350-354.
51. Swartz KL, Pratt LA, Armenian HK, Lee LC, Eaton WW,. Mental disorders and the incidence of migraine headaches in a community sample. Arch Gen Psychiatry. 2000; 57: 945-950.
52. Juang KD, Wang SJ, Fuh JL, Lu SR, Su TP,. Comorbidity of depressive and anxiety disorders in chronic daily headache and its subtypes. Headache. 2000; 40: 818-823.
53. Mattsson P, Ekselius L,. Migraine, major depression, panic disorder, and personality traits in women aged 40-74 years: A population-based study. Cephalalgia. 2002; 22: 534-551.
54. Senaratne R, Van Ameringen M, Mancini C, Patterson B, Bennet M,. The prevalence of migraine headaches in an anxiety disorders clinic sample. CNS Neurosci Ther. 2010; 16: 76-82.
55. Yamada K, Moriwaki K, Oiso H, Ishigooka J,. High prevalence of comorbidity of migraine in outpatients with panic disorder and effectiveness of psychopharmacotherapy for both disorders: A retrospective open label study. Psychiatry Res. 2011; 185: 145-148.
56. Talati A, Ponniah K, Strug LJ, Hodge SE, Fyer AJ, Weissman MM,. Panic disorder, social anxiety disorder, and a possible medical syndrome previously linked to chromosome 13. Biol Psychiatry. 2008; 63: 594-601.
57. Pesa J, Lage MJ,. The medical costs of migraine and comorbid anxiety and depression. Headache. 2004; 44: 562-570.
58. Stewart WF, Linet MS, Celentano DD,. Migraine headaches and panic attacks. Psychosom Med. 1989; 51: 559-569.
59. Buse DC, Rupnow MF, Lipton RB,. Assessing and managing all aspects of migraine: Migraine attacks, migraine-related functional impairment, common comorbidities, and quality of life. Mayo Clin Proc. 2009; 84: 422-435.
60. Lake AE III,. Medication overuse headache: Biobehavioral issues and solutions. Headache. 2006; 46 (Suppl. 3): S88-S97.
61. Radat F, Creac'h C, Swendsen JD, et al. Psychiatric comorbidity in the evolution from migraine to medication overuse headache. Cephalalgia. 2005; 25: 519-522.
62. Seng EK, Holroyd KA,. Psychiatric comorbidity and response to preventative therapy in the treatment of severe migraine trial. Cephalalgia. 2012; 32: 390-400.
63. Heckman BD, Holroyd KA, Himawan L, et al. Do psychiatric comorbidities influence headache treatment outcomes? Results of a naturalistic longitudinal treatment study. Pain. 2009; 146: 56-64.
64. Smitherman TA, Penzien DB,. Were we wrong about the role of psychiatric comorbidities in primary headache? Pain. 2009; 146: 11-12.
65. Merikangas KR, Angst J, Isler H,. Migraine and psychopathology. Results of the Zurich cohort study of young adults. Arch Gen Psychiatry. 1990; 47: 849-853.
66. American Psychiatric Association. Practice Guideline for the Treatment of Patients with Panic Disorder, 2nd edn. Washington, DC: American Psychiatric Association; 2009.
67. Hamel E,. Serotonin and migraine: Biology and clinical implications. Cephalalgia. 2007; 27: 1295-1300.
68. Goadsby PJ, Charbit AR, Andreou AP, Akerman S, Holland PR,. Neurobiology of migraine. Neuroscience. 2009; 161: 327-341.
69. Zwangzer P, Rupprecht R,. Selective GABAergic treatment for panic? Investigations in experimental panic induction and panic disorder. Neurol Sci. 2005; 30: 167-175.
70. D'Andrea G, Granella F, Cataldini M, Verdelli F, Balbi T,. GABA and glutamate in migraine. J Headache Pain. 2001; 2 (Suppl. 1): 57-60.
71. Storer RJ, Akerman S, Shields KG, Goadsby PJ,. GABAA receptor modulation of trigeminovascular nociceptive neurotransmission by midazolam is antagonized by flumazenil. Brain Res. 2004; 1013: 188-193.
72. Storer PJ, Goadbsy PJ,. Topiramate inhibits trigeminovascular neurons in the cat. Cephalalgia. 2004; 24: 1049-1056.
73. Roy-Byrne PP,. The GABA-benzodiazepine receptor complex: Structure, function, and role in anxiety. J Clin Psychiatry. 2005; 66 (Suppl. 2): 14-20.
74. Shank RP, Gardocki JF, Streeter AJ, Maryanoff BE,. An overview of the preclinical aspects of topiramate: Pharmacology, pharmacokinetics, and mechanisms of action. Epilepsia. 2000; 41 (Suppl. 1): S3-S9.
75. Baskin SM, Smitherman TA,. Migraine and psychiatric disorders: Comorbidities, mechanisms, and clinical applications. Neurol Sci. 2009; 30 (Suppl. 1): S61-S65.
76. Martin VT, Behbehani M,. Ovarian hormones and migraine headache: Understanding mechanisms and pathogenesis-Part I. Headache. 2006; 46: 3-23.
77. Bigal ME, Lipton RB, Holland PR, Goadsby PJ,. Obesity, migraine and chronic migraine: Possible mechanisms of interaction. Neurology. 2007; 68: 1851-1861.
78. Peres MF, Sanchez DR, Seabra ML, et al. Hypothalamic involvement in chronic migraine. J Neurol Neurosurg Psychiatry. 2001; 71: 747-751.
79. Videbech P, Ravnkilde B,. Hippocampal volume and depression: A meta-analysis of MRI studies. Am J Psychiatry. 2004; 161: 1957-1966.
80. Kelman L,. The triggers or precipitants of the acute migraine attack. Cephalalgia. 2007; 27: 394-402.
81. Roy-Byrne CP, Craske MG, Stein MB,. Panic disorder. Lancet. 2006; 368: 1023-1032.
82. Kors EE, Vanmolkot KR, Haan J, Frants RR, van den, Maagdenberg AM, Ferrari MD,. Recent findings in headache genetics. Curr Opin Neurol. 2004; 17: 283-288.
83. Marziniak M, Mössner R, Schmitt A, Lesch KP, Sommer C,. A functional serotonin transporter gene polymorphism is associated with migraine with aura. Neurology. 2005; 64: 157-159.
84. Strug LJ, Suresh R, Talati A, et al. Panic disorder is associated with the serotonin transporter gene (SLC6A4) but not the promoter region (5- HTTLPR). Mol Psychiatry. 2010; 15: 166-176.
85. Blaya C, Salum GA, Lima MS, Leistner-Segal S, Manfro GG,. Lack of association between the Serotonin Transporter Promoter Polymorphism (5-HTTLPR) and panic disorder: A systematic review and meta-analysis. Behav Brain Funct. 2007; 3: 41.
86. Wieser T, Dresler K, Evers S, et al. No influence of 5-HTTLPR gene polymorphism on migraine symptomatology, comorbid depression, and chronification. Headache. 2010; 50: 420-430.
87. Le-Niculescu H, Balaraman Y, Niculescu A, et al. Convergent functional genomics of anxiety disorders: Translational identification of genes, biomarkers, pathways and mechanisms. Transl Psychiatry. 2011; 24: 1:e9.
88. Ligthart L, Nyholt DR, Pinninx BWJH, Boomsma DI,. The shared genetics of migraine and anxious depression. Headache. 2010; 50: 1549-1560.
89. Na HR, Kang EH, Lee JH, Yu BH,. The genetic basis of panic disorder. J Korean Med Sci. 2011; 26: 701-710.
90. Gonda X, Rihmer Z, Juhasz G, Zsombok T, Bagdy G,. High anxiety and migraine are associated with the s allele of the 5HTTLPR gene polymorphism. Psychiatry Res. 2007; 149: 261-266.
91. Hamilton SP, Fyer AJ, Durner M, et al. Further genetic evidence for a panic disorder syndrome mapping to chromosome 13q. Proc Natl Acad Sci U S A. 2003; 100: 2550-2555.
92. Weissman MM, Gross R, Fyer A, et al. Interstitial cystitis and panic disorder: A potential genetic syndrome. Arch Gen Psychiatry. 2004; 61: 273-279.
93. Peroutka SJ, Price SC, Wilhoit TL, Jones KW,. Comorbid migraine with aura, anxiety, and depression is associated with dopamine D2 receptor (DRD2) NcoI alleles. Mol Med. 1998; 4: 14-21.
94. Turk DC, Okifuji A,. Psychological factors in chronic pain: Evolution and revolution. J Consult Clin Psychol. 2002; 70: 678-690.
95. Vlaeyen JWS, Linton SJ,. Fear-avoidance and its consequences in chronic musculoskeletal pain: A state of the art. Pain. 2000; 85: 317-322.
96. Vlaeyen JWS, Linton SJ,. Fear-avoidance model of chronic musculoskeletal pain: 12 years on. Pain. 2012; 153: 1144-1147.
97. Bouton ME, Mineka S, Barlow DH,. A modern learning theory perspective on the etiology of panic disorder. Psychol Rev. 2001; 108: 4-32.
98. De Cort DC, Griez E, Buchler M, Schruers K,. The role of "interoceptive" fear conditioning in the development of panic disorder. Behav Ther. 2012; 43: 203-215.
99. De Peuter S, Van Diest I, Vansteenwegen D, Vanden Bergh O, Vlaeyen JWS,. Understanding fear of pain in chronic pain: Interoceptive fear conditioning as a novel approach. Eur J Pain. 2011; 15: 889-894.
100. McCracken LM, Zayfert C, Gross RT,. The Pain Anxiety Symptoms Scale: Development and validation of a scale to measure fear of pain. Pain. 1992; 50: 67-73.
101. Asmundson GJG, Norton PJ, Norton GR,. Beyond pain: The role of fear and avoidance in chronicity. Clin Psychol Rev. 1999; 19: 97-119.
102. Crombez G, Vlaeyen JW, Heuts PH, Lysens R,. Pain-related fear is more disabling than pain itself: Evidence of the role of pain-related fear in chronic back pain disability. Pain. 1999; 80: 329-339.
103. Turk DC, Wilson HD,. Fear of pain as a prognostic factor in chronic pain: Conceptual models, assessment, and treatment implications. Curr Pain Headache Rep. 2010; 14: 88-95.
104. Nash JM, Williams DM, Nicholson R, Trask PC,. The contribution of pain-related anxiety to disability from headache. J Behav Med. 2006; 29: 61-67.
105. Hursey KG, Jacks SD,. Fear of pain in recurrent headache sufferers. Headache. 1992; 32: 283-286.
106. Norton PJ, Asmundson GJG,. Anxiety sensitivity, fear, and avoidance behavior in headache pain. Pain. 2004; 111: 218-223.
107. Greenberg J, Burns JW,. Pain anxiety among chronic pain patients: Specific phobia or manifestation of anxiety sensitivity. Behav Res Ther. 2003; 41: 223-240.
108. Taylor S,. Anxiety Sensitivity: Theory, Research and Treatment of the Fear of Anxiety. Hillsdale, NJ: Erlbaum; 1999.
109. Taylor S, Zvolensky MJ, Cox BJ, et al. Robust dimensions of anxiety sensitivity: Development and initial validation of the Anxiety Sensitivity Index-3. Psychol Assess. 2007; 19: 176-188.
110. Clark DM,. A cognitive approach to panic. Behav Res Ther. 1986; 24: 461-470.
111. Fava L, Morton J,. Causal modeling of panic disorder theories. Clin Psychol Rev. 2009; 29: 623-637.
112. Schmidt NB, Zvolensky MJ, Maner JK,. Anxiety sensitivity: Prospective prediction of panic attacks and Axis I pathology. J Psychiatr Res. 2006; 40: 691-699.
113. Olatunji MO, Wolitzky-Taylor KB,. Anxiety sensitivity and the anxiety disorders: A meta-analytic review and synthesis. Psychol Bull. 2009; 136: 974-999.
114. Asmundson GJG, Taylor S,. Role of anxiety sensitivity in pain-related fear and avoidance. J Behav Med. 1996; 19: 577-586.
115. Ocanez KLS, McHugh RK, Otto MW,. A meta-analytic review of the association between anxiety sensitivity and pain. Depress Anxiety. 2010; 27: 760-767.
116. Asmundson GJG, Norton PJ, Veloso F,. Anxiety sensitivity and fear of pain in patients with recurring headaches. Behav Res Ther. 1999; 37: 703-713.
117. Barlow DH,. Anxiety and Its Disorders. New York, NY: Guilford; 2002.
118. Martin PR, MacLeod C,. Behavioral management of headache triggers: Avoidance of triggers is an inadequate strategy. Clin Psychol Rev. 2009; 29: 483-495.
119. Martin PR,. Headache triggers: To avoid or not to avoid, that is the question. Psychol Health. 2000; 15: 801-809.
120. Martin PR, Reece J, Forsyth M,. Noise as a trigger for headaches: Relationship between exposure and sensitivity. Headache. 2006; 46: 962-972.
121. Spitzer RL, Kroenke K, Williams JBW, and the Patient Health Questionnaire Study Group. Validity and utility of a self-report version of PRIME-MD: The PHQ Primary Care Study. JAMA. 1999; 282: 1737-1744.
122. Spitzer RL, Kroenke K, Williams JBW, Löwe B,. A brief measure for assessing generalized anxiety disorder. Arch Intern Med. 2006; 166: 1092-1097.
123. Kroenke K, Spitzer RL, Williams JBW, et al. Anxiety disorders in primary care: Prevalence, impairment, comorbidity, and detection. Ann Intern Med. 2007; 146: 317-325.
124. Beck AT, Epstein N, Brown G, Steer RA,. An inventory for measuring clinical anxiety: Psychometric properties. J Consult Clin Psychol. 1988; 56: 893-897.
125. Spielberger C, Gorsuch RL, Lushene R, Vagg PR, Jacobs GA,. Manual for the State-Trait Anxiety Inventory. Palo Alto, CA: Consulting Psychologists Press; 1983.
126. Bieling J, Antony MM, Swinson RP,. The State-Trait Anxiety Inventory: Structure and content re-examined. Behav Res Ther. 1998; 36: 777-788.
127. Rapee RM, Craske MG, Barlow DH,. Assessment instrument for panic disorder that includes fear of sensation-producing activities: The Albany Panic and Phobia Questionnaire. Anxiety. 1995; 1: 114-122.
128. McCracken LM, Dhingra L,. A short version of the Pain Anxiety Symptoms Scale (PASS-20): Preliminary development and validity. Pain Res Manag. 2002; 7: 45-50.
129. Silberstein SD, Holland S, Dodick DW, Argoff C, Ashman E,. Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012; 78: 1337-1345.
130. Koen M, Stein DJ,. Pharmacotherapy of anxiety disorders: A critical review. Dialogues Clin Neurosci. 2011; 13: 423-437.
131. Bakker A, van Balkom AJLM, Spinhoven P,. SSRIs vs. TCAs in the treatment of panic disorder: A meta-analysis. Acta Psychiatr Scand. 2002; 106: 163-167.
132. Mitte K,. A meta-analysis of the efficacy of psycho- and pharmacotherapy in panic disorder with and without agoraphobia. J Affect Disord. 2005; 88: 27-45.
133. Silberstein SD, Dodick D, Freitag F, et al. Pharmacological approaches to managing migraine and associated comorbidities-Clinical considerations for monotherapy versus polytherapy EFNS guideline on the drug treatment of migraine-Revised report of an EFNS task force. Eur J Neurol. 2007; 16: 968-981.
134. Ramadan NM, Silberstein SD, Freitag FG, Gilbert TT, Frishberg BM,. Evidence-based guidelines for migraine headache in the primary care setting: Pharmacological management for prevention of migraine. 2000. Available at: http://www.aan.com/professionals/practice/pdfs/gl0090.pdf (accessed September 18, 2012).
135. Evers S, Áfra J, Fresea A, et al. EFNS guideline on the drug treatment of migraine-Revised report of an EFNS task force. Eur J Neurol. 2009; 16: 968-981.
136. Moja L, Cusi C, Sterzi R, Canepari C,. Selective serotonin re-uptake inhibitors (SSRIs) for preventing migraine and tension-type headaches. Cochrane Database Syst Rev. 2005;(3) CD002919. doi: 10.1002/14651858.CD002919.pub2.
137. Smitherman TA, Walters AB, Maizels M, Penzien DB,. The use of antidepressants for headache prophylaxis. CNS Neurosci Ther. 2011; 17: 462-469.
138. Pollack MH, Simon NM,. Pharmacotherapy for panic disorder and agoraphobia. In:, Antony MM, Stein MB, eds. Oxford Handbook of Anxiety and Related Disorders. New York, NY: Oxford University Press; 2009: 295-307.
139. Griffith JL, Razavi M,. Pharmacological management of mood and anxiety disorders in headache patients. Headache. 2006; 46 (Suppl. 3): S133-S141.
140. Evans RW, Tepper SJ, Shapiro RE, Sun-Edelstein C, Tietjen GE,. The FDA alert on serotonin syndrome with use of triptans combined with selective serotonin reuptake inhibitors or selective serotonin-norepinephrine reuptake inhibitors: American Headache Society position paper. Headache. 2010; 50: 1089-1099.
141. Gillman PK,. Triptans, serotonin agonists, and serotonin syndrome (serotonin toxicity): A review. Headache. 2010; 50: 264-272.
142. Craske MG, Barlow DH,. Mastery of Your Anxiety and Panic, 4th edn, therapist guide. New York, NY: Oxford University Press; 2007.
143. Sánchez-Meca J, Rosa-Alcàzar AI, Marín- Martínez F, Gõmez-Conesa A,. Psychological treatment of panic disorder with or without agoraphobia: A meta-analysis. Clin Psychol Rev. 2010; 30: 37-50.
144. Foa EB, Kozak MJ,. Emotional processing of fear: Exposure to corrective information. Psychol Bull. 1986; 99: 20-35.
145. Bakker A, van Balkom AJ, Spinhoven P, Blaauw BM, van, Dyck R,. Follow-up on the treatment of panic disorder with or without agoraphobia: A quantitative review. J Nerv Ment Dis. 1998; 186: 414-419.
146. Norton PJ, Price EC,. A meta-analytic review of adult cognitive-behavioral treatment outcome across the anxiety disorders. J Nerv Ment Dis. 2007; 195: 521-531.
147. van Balkom AJ, Bakker A, Spinhoven P, Blaauw BM, Smeenk S, Ruesink B,. A meta-analysis of the treatment of panic disorder with or without agoraphobia: A comparison of psychopharmacological, cognitive-behavioral, and combination treatments. J Nerv Ment Dis. 1997; 185: 510-516.
148. Gould RA, Otto MW, Pollack MH,. A meta-analysis of treatment outcome for panic disorder. Clin Psychol Rev. 1995; 15: 819-844.
149. Barlow DH, Gorman JM, Shear MK, Woods SW,. Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial. JAMA. 2000; 283: 2529-2536.
150. Fava GA, Rafanelli C, Grandi S, et al. Long-term outcome of panic disorder with agoraphobia treated by exposure. Psychol Med. 2001; 31: 891-898.
151. Bruce TJ, Spiegel DA, Hegel MT,. Cognitive-behavioral therapy helps prevent relapse and recurrent of panic disorder following alprazolam discontinuation: A long-term follow-up of the Peoria and Dartmouth studies. J Consult Clin Psychol. 1999; 67: 151-156.
152. Otto MW, McHugh RK, Simon NM, Farach FJ, Worthington JJ, Pollack MH,. Efficacy of CBT for benzodiazepine discontinuation in patients with panic disorder: Further evaluation. Behav Res Ther. 2010; 48: 720-727.
153. Otto MW, Pollack MH,. Stopping Anxiety Medication, 2nd edn, therapist guide. New York, NY: Oxford University Press; 2009.
154. Côté G, Gauthier JG, Laberge B, et al. Reduced therapist contact in the cognitive behavioral treatment of panic disorder. Behav Ther. 1994; 25: 123-145.
155. Craske MG, Maidenberg E, Bystritsky A,. Brief cognitive-behavioral versus non-directive therapy for panic disorder. J Behav Ther Exp Psychiatry. 1995; 26: 113-120.
156. Kenardy JA, Dow MGT, Johnston DW, Newman MG, Thomson A, Taylor CB,. A comparison of delivery methods of cognitive-behavioral therapy for panic disorder: An international multicenter trial. J Consult Clin Psychol. 2003; 71: 1068-1075.
157. Roy-Byrne P, Veitengruber JP, Bystritsky A, et al. Brief intervention for anxiety in primary care patients. J Am Board Fam Med. 2009; 22: 175-186.
158. Swinson RP, Soulios C, Cox BJ, Kuch K,. Brief treatment of emergency room patients with panic attacks. Am J Psychiatry. 1992; 149: 944-946.
159. Lipchik GL, Smitherman TA, Penzien DB, Holroyd K,. Basic principles and techniques of cognitive-behavioral therapies for comorbid psychiatric symptoms among headache patients. Headache. 2006; 46 (Suppl. 3): 119-132.
160. Smitherman TA, Maizels MM, Penzien DB,. Headache chronification: Screening and behavioral management of comorbid depressive and anxiety disorders. Headache. 2008; 48: 45-50.
161. Ratcliffe GE, Enns MW, Jacobi F, Belik SL, Sareen J,. The relationship between migraine and mental disorders in a population-based sample. Gen Hosp Psychiatry. 2009; 3: 14-19.
162. Kalaydjian A, Merikangas K,. Physical and mental comorbidity of headache in a nationally representative sample of US adults. Psychosom Med. 2008; 70: 773-780.
163. Jette N, Patten S, Williams J, Becker W, Wiebe S,. Comorbidity of migraine and psychiatric disorders-A national population-based study. Headache. 2008; 48: 501-516.
164. Smoller JW, Pollack MH, Wassertheil-Smoller S, et al. Prevalence and correlates of panic attacks in postmenopausal women: Results from an ancillary study to the Women's Health Initiative. Arch Intern Med. 2003; 163: 2041-2050.
165. Beghi E, Bussone G, D'Amico D, et al. Headache, anxiety and depressive disorders: The HADAS study. J Headache Pain. 2010; 11: 141-150.
166. Mongini F, Rota E, Deregibus A, et al. Accompanying symptoms and psychiatric comorbidity in migraine and tension-type headache patients. J Psychosom Res. 2006; 61: 447-451.
167. Mehlsteibl D, Schankin C, Hering P, Sostak P, Straube A,. Anxiety disorders in headache patients in a specialized clinic: Prevalence and symptoms in comparison to patients in a general neurological clinic. J Headache Pain. 2011; 12: 323-329.
168. Breslau N, Davis GC, Andreski P,. Migraine, psychiatric disorders, and suicide attempts: An epidemiologic study of young adults. Psychiatry Res. 1991; 37: 11-23.
169. Breslau N, Davis GC,. Migraine, major depression and panic disorder: A prospective epidemiologic study of young adults. Cephalalgia. 1992; 12: 85-90.
170. Breslau N, Davis GC,. Migraine, physical health and psychiatric disorder: A prospective epidemiologic study in young adults. J Psychiatr Res. 1993; 27: 211-221.